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Purpose
This study was conducted to evaluate clinical outcomes following definitive concurrent
chemoradiotherapy (CCRT) for patients with N3-positive stage IIIB (N3-IIIB) non-small cell
lung cancer (NSCLC), with a focus on radiation therapy (RT) techniques.
Materials and Methods
From May 2010 to November 2012, 77 patients with N3-IIIB NSCLC received definitive
CCRT (median, 66 Gy). RT techniques were selected individually based on estimated lung
toxicity, with 3-dimensional conformal RT (3D-CRT) and intensity-modulated RT (IMRT) 
delivered to 48 (62.3%) and 29 (37.7%) patients, respectively. Weekly docetaxel/paclitaxel
plus cisplatin (67, 87.0%) was the most common concurrent chemotherapy regimen.
Results
The median age and clinical target volume (CTV) were 60 years and 288.0 cm3, respectively.
Patients receiving IMRT had greater disease extent in terms of supraclavicular lymph node
(SCN) involvement and CTV ! 300 cm3. The median follow-up time was 21.7 months. Forty-
five patients (58.4%) experienced disease progression, most frequently distant metastasis
(39, 50.6%). In-field locoregional control, progression-free survival (PFS), and overall survival
(OS) rates at 2 years were 87.9%, 38.7%, and 75.2%, respectively. Although locoregional
control was similar between RT techniques, patients receiving IMRT had worse PFS and OS,
and SCN metastases from the lower lobe primary tumor and CTV ! 300 cm3 were associated
with worse OS. The incidence and severity of toxicities did not differ significantly between
RT techniques.
Conclusion
IMRT could lead to similar locoregional control and toxicity, while encompassing a greater
disease extent than 3D-CRT. The decision to apply IMRT should be made carefully after 
considering oncologic outcomes associated with greater disease extent and cost.
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Introduction
Definitive concurrent chemoradiotherapy (CCRT) has 
become the standard treatment for patients with N3-positive
stage IIIB (N3-IIIB) non-small cell lung cancer (NSCLC) 
[1-4]. Delivery of high radiation dose, which is usually 
recommended for improved locoregional control and 
survival [5], is often limited by the risk of lung toxicity, 
which presents as radiation pneumonitis and subsequent
pulmonary fibrosis [6,7]. The extent of metastatic regional
lymph nodes (LN) in patients with N3-IIIB NSCLC is quite
heterogeneous [8], and it often becomes difficult to safely
cover the whole disease extent within the high radiation dose
volume when using conventional 3-dimensional conformal
radiation therapy (3D-CRT) technique. Metastasis to the
supraclavicular lymph node (SCN) from the lower lobe 
primary tumor is a typical problematic example. Introduc-
tion of the intensity-modulated radiation therapy (IMRT)
technique has greatly improved the target coverage at high
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radiation dose while sparing normal lung tissue [9-11]. 
Previous studies that employed IMRT were more or less 
successful at achieving favorable clinical outcomes in terms
of locoregional control and survival and reducing the inci-
dences of pulmonary and esophageal toxicities, among
which the proportion of patients with N3 or IIIB disease 
accounted for 32%-60% [12-14]. Based on these studies, the
use of IMRT for treatment of patients with stage III NSCLC
has become increasingly popular [15]. 
The use of IMRT is still limited in Korea, mainly because
the national health insurance plan covers only the 3D-CRT
technique and does not reimburse the cost of IMRT during
treatment of patients with NSCLC. Given this limitation, few
clinical studies on the use of IMRT for lung cancer patients
have been conducted in Korea [16]. Since May of 2010, the
authors at Samsung Medical Center (SMC) have been using
IMRT to treat patients with extensive NSCLC. Based on their
known disease extent, these patients were believed to be at
excessive risk of pulmonary toxicity if treated with conven-
tional 3D-CRT. This study was conducted to comparatively
evaluate treatment outcomes based on the radiation therapy
(RT) techniques chosen (IMRT vs. 3D-CRT) for evaluation of
N3-IIIB NSCLC patients receiving definitive CCRT.
Materials and Methods
From May 2010 to November 2012, 81 patients with newly
diagnosed, pathologically confirmed N3-IIIB NSCLC were
treated with definitive CCRT at SMC. Since trimodality ther-
apy strategy, which includes surgical resection following
neoadjuvant CCRT, has been the primary treatment option
for N2-IIIA patients at SMC [17], patients with N3-IIIB 
disease constituted the majority of those receiving definitive
CCRT. Among these, two patients received curative surgical
resection following definitive CCRT, and another two 
received a combination of 3D-CRT and IMRT. After exclud-
ing these four patients, we retrospectively reviewed the med-
ical records of 77 patients who were the basis of the current
study. The RT techniques were selected individually based
on the known disease extent, performance and cardio-
pulmonary functional status of the patients, and the subse-
quent estimated risk of pulmonary toxicity. When the esti-
mated V20 exceeded 40%, the mean lung dose exceeded 25
Gy, and/or the maximum spinal cord dose exceeded 50 Gy
if treated with conventional 3D-CRT, they were offered the
IMRT option. It was explained to all the IMRT candidate 
patients that IMRT was not covered by the Korean insurance
policy, and they were offered alternative option of induction
chemotherapy followed by sequential RT in case the IMRT
cost was not affordable. All IMRT candidate patients agreed
to pay the extra-cost, and the current study was approved by
the Institutional Review Board of Samsung Medical Center
(2013-08-027). 
The initial diagnosis of NSCLC was pathologically 
confirmed in all patients based on either bronchoscopy or
percutaneous fine-needle aspiration and biopsy. The diag-
nostic and staging work-ups included complete history 
and physical examination, simple chest radiographs, chest
computed tomography (CT) scan, routine blood tests, and
18fluoro-deoxyglucose positron emission tomography (PET)
or PET/CT scan. For accurate nodal staging, fine-needle 
aspiration from the SCN was performed in 33 patients
(42.9%), endobronchial ultrasound-guided transbronchial
needle aspiration in 29 (37.7%), and mediastinoscopic biopsy
in nine (9.1%). N3 stage assignment was made primarily
based on clinical judgment without histologic confirmation
in 15 patients (19.5%) who showed abnormal findings on
PET/CT scan and were at very high risk to undergo any 
invasive procedures. 
For treatment planning, contrast enhancing simulation CT
scans of all patients were conducted. Simulation CT scans
were typically performed in the supine position at a thick-
ness of 2.5-5 mm. The gross tumor volume (GTV) was 
defined as the volume of the tumor identified based on all
available clinical information, including radiologic imaging,
PET scan, bronchoscopy, and mediastinoscopy. The clinical
target volume (CTV) was delineated by a 5-mm margin 
extending in all directions from the GTV, and the margins
were modified in accordance with the adjacent organs if 
necessary. The internal target volume was delineated by
combining all GTVs and CTVs delineated on each respira-
tory phase based on 4-dimensional computed tomography
(4D-CT), which was acquired in 29 patients (37.7%). Elective
irradiation of the clinically uninvolved lymph node was not
allowed principally. A 5-8 mm margin extension around the
CTV was included to generate the planning target volume.
The Pinnacle3 system (ver. 8.0, Philips Medical Systems,
Madison, WI) was used to calculate the radiation dose. 
During the study period, 48 patients (62.3%) were treated
with 3D-CRT (group I) and 29 (37.7%) with IMRT (group II).
The median RT dose prescribed to the CTV was 66 Gy in 33
fractions over 6.5 weeks. The 3D-CRT plan was typically
composed of three or four beams of 4-, 6-, or 10-MV photons
from a linear accelerator (Varian Medical System, Palo Alto,
CA). The IMRT plan was mainly composed of six median
coplanar beams of 6-MV photons using the step-and-shoot
method. Whenever feasible and indicated, the second CT
simulation and adaptive re-plan was generated to accommo-
date tumor regression and reduce the normal tissue toxicity,
typically at fractions of 20-23. The normal tissue constraints
used were as follows: maximum spinal cord dose < 46 Gy;
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relative lung volumes receiving 20 Gy/5 Gy < 35%/< 65%;
and the mean lung dose < 20 Gy. The most common concur-
rent chemotherapeutic regimen was weekly paclitaxel or 
docetaxel plus cisplatin or carboplatin, which was adminis-
tered to 67 patients (87.0%). Ten of these patients received
additional consolidation chemotherapy following CCRT. 
The remaining ten patients (13.0%) received pemetrexed or
etoposide plus cisplatin, while nine of these patients received
consolidation chemotherapy. 
The first follow-up and response evaluation was scheduled
at 1 month after completion of CCRT and included a chest
CT scan. Subsequent follow-up evaluations were conducted
at 3-4 month intervals thereafter, and included alternating
chest CT and whole-body PET/CT scans. The early toxicities
of treatment-related pneumonitis (TRP) and esophagitis
were graded using the Common Terminology Criteria 
for Adverse Events (CTCAE), ver. 4.0. The primary end-
points were the progression-free survival (PFS) and the over-
all survival (OS), while the secondary endpoints were the
in-field locoregional control (LRC) and patterns of disease
progression. All intervals were calculated from the dates of
the CCRT start until the events or the latest follow-up. 
In-field locoregional progression was defined as disease 
progression within the irradiated volume inside the thorax,
and included the ipsilateral hilum, ipsilateral and/or con-
tralateral mediastinum, and ipsilateral and/or contralateral
SCN, but not hematogenous lung-to-lung metastasis.
A chi-square test was used to compare the patients’ clinical
characteristics and the dose-volume parameters based on the
RT techniques used. A t test was used to compare continuous
variables such as age, forced expiratory volume in 1 second,
and tumor size. The rates of PFS, OS, and LRC were calcu-
lated and compared using the Kaplan-Meier method and the
log-rank test, respectively. Factors having a p-value of < 0.2
upon univariate analysis were entered into Cox proportional
hazards regression analysis. A p-value of ! 0.05 was consid-
ered statistically significant, and the SAS software (ver. 9.1.3,
SAS Institute Inc., Cary, NC) was used for statistical analy-
ses.
Table 1. Clinical characteristics according to radiotherapy technique
Characteristic 3D-CRT (n=48) IMRT (n=29) p-value
Age (yr) 62 (44-72) 59 (40-80) 0.744
Sex
Male 35 (72.9) 18 (62.1) 0.390
Female 13 (27.1) 11 (37.9)
Smoking history 34 (70.8) 17 (58.6) 0.272
FEV1 (L) 2.49 (1.17-3.90) 2.50 (1.46-3.71) 0.791
ECOG performance
0 10 (20.8) 6 (20.7) 0.988
1 38 (79.2) 23 (79.3)
Primary site
Upper-middle lobes 39 (81.3) 13 (44.8) 0.001
Lower lobes 9 (18.7) 16 (55.2)
Histology
Adenocarcinoma 31 (64.6) 22 (75.9) 0.053
Squamous cell carcinoma 15 (31.2) 3 (10.3)
Others 2 (4.2) 4 (13.8)
Tumor size (cm) 3.8 (1.3-12.2) 3.7 (1.0-9.2) 0.785
Clinical T classification
cT1-2 34 (70.8) 23 (79.3) 0.411
cT3-4 14 (29.2) 6 (20.7)
N3 involvement region
Contralateral mediastinum 29 (60.4) 7 (24.1) 0.002
Supraclavicular 26 (54.2) 24 (82.8) 0.011
Values are presented as median (range) or number (%). 3D-CRT, three-dimensional conformal radiotherapy; IMRT, inten-
sity-modulated radiotherapy; FEV1, forced expiratory volume in 1 second; ECOG, Eastern Cooperative Oncology Group.
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Results
The clinical characteristics based on the RT techniques are
summarized in Table 1. The median age of all patients was
60 years (range, 40 to 80 years). Age, sex, smoking history,
performance status, and clinical T classification did not differ
between groups. Adenocarcinoma was the most common
histology (53 patients, 68.8%), followed by squamous cell 
carcinoma (18 patients, 23.4%). The median tumor size meas-
ured on the initial CT was 3.8 cm (range, 1.0 to 12.2 cm).
Group II (IMRT) patients had significantly more frequent 
primary tumors located in the lower lobes (p=0.001) and
SCN involvement (p=0.011) than group I (3D-CRT). Among
50 patients with SCN involvement, 16 had primary tumors
located in the lower lobes, which was also more frequent in
group II than in group I (13/24 patients, 54.2% vs. 3/26 
patients, 11.5%). The median CTV of all patients was 288.0
cm3 (range, 89.3 to 1,543.3 cm3). Although the median CTV
tended to be larger in group II than group I (3D-CRT), this
difference was not statistically significant according to a t test
(p=0.706) (Table 2). When the CTVs were stratified into
groups (< 300 cm3 vs. " 300 cm3), group II was associated
with larger CTV more frequently than group I (p=0.043).
Since patients receiving IMRT generally had a greater extent
Table 2. Dose-volume parameters according to radiotherapy techniques
Variable 3D-CRT (n=48) IMRT (n=29) p-value
CTV (cm3) 279.3 (89.4-1,543.3) 357.5 (89.3-762.7) 0.706
CTV
< 300 cm3 28 (59.3) 10 (34.5) 0.043
" 300 cm3 20 (41.7) 19 (65.5)
Total lung
Mean dose (Gy) 18.4 (9.3-28.0) 19.6 (14.6-25.2) 0.031
V5 (%) 57.2 (29.8-72.9) 65.1 (48.4-90.0) < 0.001
V10 (%) 48.6 (24.5-63.5) 51.8 (41.8-62.9) 0.107
V15 (%) 40.6 (18.1-54.5) 42.3 (34.7-53.6) 0.052
V20 (%) 32.8 (14.3-50.0) 35.6 (28.2-45.9) 0.061
Esophagus
Maximum dose (Gy) 67.1 (55.3-74.7) 68.4 (60.0-77.3) 0.007
Mean dose (Gy) 33.2 (12.5-55.8) 35.1 (16.1-52.0) 0.111
V30 (%) 52.1 (15.2-87.7) 55.9 (15.8-79.6) 0.520
V45 (%) 44.2 (3.7-74.9) 48.8 (1.2-76.5) 0.526
Spinal cord
Maximum dose (Gy) 43.9 (10.5-57.4) 43.1 (32.3-48.4) 0.708
Heart
Median dose (Gy) 8.6 (0.5-42.4) 16.4 (1.5-35.0) 0.001
Values are presented as median (range) or number (%). 3D-CRT, three-dimensional conformal radiotherapy; IMRT, inten-
sity-modulated radiotherapy; CTV, clinical target volume; VD, percentage volume of organ receiving " D Gy. 
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Fig. 1.  Dose-volume parameters for lung and esophagus
in patients with supraclavicular lymph node (SCN) orig-
inating from a lower lobe primary tumor. 3D-CRT, 
3-dimensional conformal radiation therapy; IMRT, inten-
sity-modulated radiation therapy; LV5 and LV20, 
volumes of the normal lung received " 5 Gy and " 20 Gy;
MLD, mean lung dose; EV30 and EV45, volumes of the 
normal esophagus received " 30 Gy and " 45 Gy; MED,
mean esophagus dose. Data are presented as the mean±
standard error.
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of disease, the mean lung and heart doses were higher in
group II than in group I. However, the normal tissue doses
generally met the constraints described above. Among the
16 patients with SCN metastasis from the lower lobe primary
tumors, dose-volume parameters for the lungs and esopha-
gus were generally similar (Fig. 1).
The median follow-up duration was 21.7 months (range,
2.3 to 43.1 months). During the follow-up period, 45 patients
(58.4%) experienced disease progression (Table 3). The most
common first failure pattern was distant metastasis observed
in 39 patients (50.6%), followed by locoregional progression
in 13 patients (16.9%). Among 13 patients with locoregional
failure, nine showed progression within the RT volume, six
from group I and three from group II. There were seven 
patients (9.1%) who presented with both locoregional and
distant progression. The organs involved via distant metas-
tasis were the lung in 12 patients, the brain in nine, bone in
eight, and the liver in five. The median duration of PFS was
11.1 months, and the 1- and 2-year rates of PFS were 47.9%
and 38.7%, respectively (Fig. 2). The 1- and 2-year rates of 
in-field LRC were 87.9% and 85.0%, respectively. A total of
18 patients (23.4%) died during the follow-up period. 
Pulmonary causes, such as pneumonia, pneumonitis, and
acute respiratory distress syndrome, were responsible for the
deaths of two patients, one from group I and the other from
group II, while TRP was not the direct cause of death for two
patients. In addition, one patient died of myocardial infarc-
tion. The 1- and 2-year rates of OS were 85.5% and 75.2%, 
respectively (Fig. 2). The incidence of CTACE grade 3
esophagitis was 19.5%, which was not different between
groups I and II (14.6% vs. 27.6%, p=0.163). Although 
patients receiving IMRT had significantly larger disease 
extent and received higher lung dose, the incidence of grade
" 2 pneumonitis was not higher in group II than group I
(33.3% vs. 24.1%, p=0.393). Among the 16 patients with SCN
metastasis from the lower lobe primary tumor, grade " 2
pneumonitis developed in three patients, one from group I
and two from group II. Grade 3 esophagitis occurred in four
patients in group II.
The clinical outcomes based on the probable prognostic
factors are summarized in Tables 4 and 5. According to 
univariate analyses, IMRT technique (p=0.001), age < 60
Table 3. Outcomes according to treatment groups
Variable 3D-CRT (n=48) IMRT (n=29) Overall (n=77)
Disease progression 24 (50.0) 21 (72.4) 45 (58.4)
Time to progression (mo) 9.1 (3.9-35.0) 6.0 (2.5-15.9) 8.2 (2.5-35.0)
Patterns of failures
Locoregional 4 (8.3) 2 (6.9) 6 (7.8)
Distant 17 (35.4) 15 (51.7) 32 (41.6)
Both 3 (6.3) 4 (13.8) 7 (9.1)
Esophagitis
Grade ! 2 41 (85.4) 21 (72.4) 62 (80.5)
Grade 3 7 (14.6) 8 (27.6) 15 (19.5)
Pneumonitis
Grade 1 32 (66.7) 22 (75.9) 54 (70.1)
Grade " 2 16 (33.3) 7 (24.1) 23 (29.9)
Values are presented as number (%) or median (range). 3D-CRT, three-dimensional conformal radiotherapy; IMRT, inten-
sity-modulated radiotherapy.
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Fig. 2.  Progression-free survival (PFS) and overall 
survival (OS) after definitive concurrent chemoradiother-
apy in patients with N3-positive stage IIIB non-small cell
lung cancer.
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years (p=0.019), and non-squamous cell carcinoma histology
(p=0.002) were associated with significantly poor PFS, while
IMRT technique (p=0.007), SCN metastasis from the lower
lobe primary tumor (p=0.019), and CTV " 300 cm3 (p=0.001)
were associated with significantly poor OS. Gender, clinical
T stage, and SCN involvement itself were not of prognostic
value to the clinical outcomes. No specific factor was known
to have affected the in-field LRC. Based on multivariate
analyses, IMRT technique (p=0.010) and age < 60 years
(p=0.032) were significant poor prognostic factors affecting
the PFS. Interestingly, the RT technique was not a significant
factor affecting the OS (p=0.197), while a CTV " 300 cm3 was
the only factor that had a significant effect on the OS
(p=0.018).
Discussion
Few studies have reported the treatment outcomes follow-
ing IMRT for NSCLC [12-14,16,18]. These previous studies
not only included patients with stage IIIB disease, but also
those with stage IIIA and even stages I/II. Although the 
current study included only N3-IIIB patients, the disease 
extent was still quite heterogeneous because of differences
in the location of metastatic LNs and the CTVs. Despite 
definitive CCRT being the standard treatment option for 
patients with N3-IIIB NSCLC, 3D-CRT cannot safely deliver
high radiation doses cases of large disease extent, especially
in those involving SCN metastasis from lower lobe primary 
tumors, because of the normal tissue toxicity risk. Based on
previously conducted studies, IMRT could result in signifi-
cantly lower levels of grade " 3 TRP when compared with
3D-CRT, despite the large GTVs [12]. Furthermore, a subse-
Table 4. Prognostic factors affecting survival outcomes upon univariate analysis in patients with N3-positive stage IIIB 
non-small cell lung cancer
Variable No. PFS OS In-field LRC
2-Year rate (%) p-value 2-Year rate (%) p-value 2-Year rate (%) p-value
Treatment group
3D-CRT 48 50.10 0.001 83.50 0.007 89.40 0.432
IMRT 29 19.30 61.70 72.40
Sex
Male 53 42.50 0.229 71.00 0.311 83.40 0.740
Female 24 30.10 85.20 87.50
Age (yr)
< 60 35 22.90 0.019 77.00 0.753 92.30 0.635
" 60 42 54.00 74.50 80.60
Histology
Adenocarcinoma 53 28.70 0.002 75.60 0.160 83.70 0.636
Squamous cell carcinoma 18 75.00 83.30 86.70
Others 6 16.70 44.40 83.30
Clinical T classification
cT1-2 48 38.70 0.904 76.80 0.722 85.10 0.948
cT3-4 29 39.00 70.00 85.20
SCN involvement
Yes 50 34.20 0.320 75.30 0.894 83.50 0.686
No 27 46.30 74.50 86.60
SCN from lower lobe
Yes 16 23.50 0.160 60.60 0.019 80.00 0.856
No 61 42.20 79.10 85.70
Clinical target volume (cm3)
< 300 38 46.00 0.139 91.20 0.001 88.40 0.834
" 300 39 31.00 59.10 80.10
PFS, progression-free survival; OS, overall survival; LRC, locoregional control; 3D-CRT, three-dimensional conformal radio-
therapy; IMRT, intensity-modulated radiotherapy; SCN, supraclavicular lymph node.
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quent study showed that IMRT with 4D-CT was associated
with reduced toxicity and improved OS [13]. Following the
median follow-up of 16.5 months, the 2-year rates of disease-
free survival and OS were 38% and 46%, respectively [14]. 
Patients receiving IMRT in the current study had signifi-
cantly more frequent SCN metastasis from the lower lobe
primary tumor and significantly larger CTVs than those 
receiving 3D-CRT. Even though group II patients had 
a larger disease extent and were therefore subjected to higher
normal tissue doses, the incidences of grade 3 esophagitis
and grade " 2 pneumonitis were not increased in this group
based on the current study. Moreover, a comparable in-field
LRC was achieved, while more frequent distant metastases
occurred in patients receiving IMRT. While the 2-year rates
of PFS and OS following definitive CCRT for patients with
N3-IIIB NSCLC were 38.7% and 75.2%, respectively, the 
corresponding rates of patients receiving IMRT were 19.3%
and 61.7%, respectively (Table 4). However, direct compari-
son of the clinical outcomes between groups I and II should
be made with caution because of the evident heterogeneity
of the clinical characteristics. Although patients receiving
IMRT had unfavorable survival outcomes, this might have
occurred because these patients already had more adverse
prognostic factors than those receiving 3D-CRT. The PFS at
2 years reported in this study seems inferior to that of previ-
ous studies (19.3% vs. 38%). This difference might have been
due to the heterogeneous patient population with respect to
stage, tumor location, and extent of nodal involvement. One
retrospective study of IMRT reported a 2-year OS rate of 58%
in stage III patients [18], and the corresponding figure by the
authors appears to be generally favorable when compared
with the previous data. Taken together, IMRT could safely
cover a larger disease extent than 3D-CRT, and yielded 
a favorable in-field LRC with no extra toxicity risk. 
As shown in Table 3, the median time to progression 
following IMRT was only 6 months, and this was mostly due
to early appearance of distant metastases. Interestingly, the
OS was not as poor as the PFS in the current study. It is 
important to note that clinical outcomes following disease
progression might be influenced by the availability of 
systemic treatment regimens, including targeting agents,
which were not presented in detail in the current study. 
Although collection of biomarker data such as mutations in
the epidermal growth factor receptor (EGFR) gene and/or
anaplastic lymphoma kinase (ALK) gene was not the primary
objective of the current study, 13 (24.5%) and five (9.4%) of
53 patients with adenocarcinoma exhibited EGFR gene 
mutations and ALK rearrangements, respectively. Further-
more, 16 of these 18 patients exhibited disease progression,
mostly distant metastases. In patients with N2-positive
NSCLC, EGFR mutation was shown to experience more 
frequent distant relapse and have worse PFS following 
preoperative CCRT and surgery at SMC [19]. CCRT accom-
panied by treatment with cetuximab, a monoclonal antibody
targeting EGFR, has demonstrated promising outcomes in
patients with stage III NSCLC [20,21]. Moreover, favorable
clinical outcomes have been reported in patients treated with
the ALK tyrosine-kinase inhibitor, crizotinib [22]. Therefore,
further improvement of clinical outcomes in the patients 
receiving definitive CCRT for N3-IIIB NSCLC could be 
expected if combining these targeting agents with RT.
As described above, the Surveillance, Epidemiology, and
End Results (SEER) data demonstrated increased use of
IMRT for patients with stage III NSCLC [15]. A radiation 
oncologists’ practice environment can strongly influence 
utilization of the IMRT technique. Similarly, the reimburse-
ment policies and practice settings were shown to have a
great effect on utilization of IMRT for treatment of patients
with breast cancer [23]. IMRT appears to have been utilized
less frequently than necessary in Korea, mainly because the
national health insurance system does not reimburse patients
for this technique. The high cost of IMRT for lung cancer
could be a considerable financial burden, resulting in finan-
cial toxicity [24,25]. Therefore, careful and reasonable deci-
sion making with consideration of the cost effectiveness
should become a crucially important issue for the optimal
Table 5. Cox proportional hazards multivariate model for survival outcomes
Variable Progression-free survival            Overall survival
HR (95% CI) p-value HR (95% CI) p-value
Treatment group 2.498 (1.246-5.008) 0.010 2.160 (0.670-6.965) 0.197
Age 0.514 (0.280-0.943) 0.032 - -
Histology 0.876 (0.490-1.564) 0.654 1.253 (0.657-2.390) 0.494
SCN from lower lobe 0.872 (0.379-2.003) 0.747 1.554 (0.490-4.927) 0.454
CTV (" 300 cm3) 1.549 (0.834-2.879) 0.166 4.665 (1.298-16.766) 0.018
HR, hazard ratio; CI, confidence interval; SCN, supraclavicular lymph node; CTV, clinical target volume.
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